News | December 04, 2014

Pocket ECG Technology Supports AF Research for Texas Cardiac Arrhythmia Research Foundation

Medi?Lynx Cardiac Monitoring LLC and MEDICALgorithmics will participate in a research project, investigating the impact of lifestyle modification on ablation outcome in atrial fibrillation (ISOLATE)

December 4, 2014 — Medi?Lynx Cardiac Monitoring LLC and MEDICALgorithmics will participate in a research project, investigating the impact of lifestyle modification on ablation outcome in atrial fibrillation (ISOLATE). The research is financed by Texas Cardiac Arrhythmia Research Foundation. The PocketECG cardiac monitoring system will be used for collecting and analyzing the ECG data in the project.

This prospective randomized pilot study will evaluate the impact of aggressive lifestyle modification, in terms of calorie?controlled diet and supervised exercise, on outcomes of catheter ablation in overweight and obese patients with atrial fibrillation. The principal investigators are Andrea Natale, M.D. with Texas Cardiac Arrhythmia Research Foundation and Mitra Mohanty, M.D., with The University of Texas at Austin.

The hypothesis states that weight loss and management by adoption of a strict diet and exercise regimen improves the chances of freedom from recurrence following catheter ablation.

One important aspect of the project is the role of autonomic neural imbalance in arrhythmogenesis. Weight?loss and aerobic exercise are believed to reverse the autonomic remodeling and enhance the electrical stability of the heart.

The trial will help to evaluate the impact of weight?loss and exercise on HRV during rest and physical activity in the intervention and no?intervention cohort.

The study’s eligible group is overweight or obese adult patients with a diagnosis of atrial fibrillation undergoing first catheter ablation at least 3 months after the enrollment.

Supervised and monitored exercise will be conducted in St. David's Cardiac Rehabilitation for at least three months before ablation. After ablation, patients will continue an individualized home?exercise program for 1 year.

For more information:

Related Content

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG | January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
Overlay Init